— Sanofi (NASDAQ: SNY) reported net loss of EUR 10 million or EUR 0.01 per share for the fourth quarter of 2019, on IFRS basis, down 103.9.% and 105% respectively, from fourth quarter of 2018.
— Business EPS, a non-GAAP measure, grew 17% at constant exchange rates to EUR 1.34.
— IFRS net sales, on a reported basis, increased 6.8% year-over-year to EUR 9.61 billion.
— Sanofi Genzyme sales rose 19.7% annually, aided by strong growth of 135% in Dupixent global sales.
— Vaccine sales increased 22%, reflecting majority of U.S. influenza vaccine shipments in Q4.
— CHC sales down 5.2%, mainly due to Zantac voluntary recall, non-core divestments and changing regulatory requirements.
— For FY20, Sanofi expects business EPS to grow about 5%, at constant exchange rates.
— SNY stock was up about 4% in the pre-market trading session.
Most Popular
MS Earnings: Morgan Stanley Q1 2025 revenue and earnings beat estimates
Morgan Stanley (NYSE: MS) on Friday reported higher revenues and net profit for the first quarter of 2025. The latest numbers also exceeded analysts’ estimates. The company reported net revenues
WFC Earnings: Key quarterly highlights from Wells Fargo’s Q1 2025 financial results
Wells Fargo & Company (NYSE: WFC) reported its first quarter 2025 earnings results today. Total revenue decreased 3% year-over-year to $20.15 billion. Net income grew 6% to $4.89 billion and
JPM Earnings: All you need to know about JPMorgan’s Q1 2025 earnings results
JPMorgan Chase & Co. (NYSE: JPM) reported its first quarter 2025 earnings results today. Reported net revenue increased 8% year-over-year to $45.3 billion. Managed net revenue was $46 billion, also
